BRPI0704816A2 - formulação lipossomal com o fármaco nistatina - Google Patents
formulação lipossomal com o fármaco nistatinaInfo
- Publication number
- BRPI0704816A2 BRPI0704816A2 BRPI0704816-5A BRPI0704816A BRPI0704816A2 BR PI0704816 A2 BRPI0704816 A2 BR PI0704816A2 BR PI0704816 A BRPI0704816 A BR PI0704816A BR PI0704816 A2 BRPI0704816 A2 BR PI0704816A2
- Authority
- BR
- Brazil
- Prior art keywords
- nystatin
- drug
- liposomal formulation
- systemic
- miscises
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 5
- 229960000988 nystatin Drugs 0.000 title abstract 5
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 title abstract 5
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 abstract 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 206010070863 Toxicity to various agents Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000011835 investigation Methods 0.000 abstract 1
- VQOXZBDYSJBXMA-RKEBNKJGSA-N nystatin a1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@@H]1OC1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C[C@](O)(CC(O)C2C(O)=O)OC2C1 VQOXZBDYSJBXMA-RKEBNKJGSA-N 0.000 abstract 1
- 150000008105 phosphatidylcholines Chemical class 0.000 abstract 1
- 238000013379 physicochemical characterization Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
FORMULAçãO LIPOSSOMAL COM O FáRMACO NISTATINA. A presente invenção trata do desenvolvimento de formulação lipossomal, contendo a Nistatina destinada a aplicações em micoses sistémicas, bem como, diminuir a toxicidade do fármaco quando aplicado na forma parenteral. A invenção é capaz de carrear o antifúngico Nistatina e promover uma liberação sustentada do referido fármaco. O invento envolve o preparo de formulação lipossomal com uma composição em percentagem molar de: 70% de Fosfatidilcolina hidrogenada (HSPC); 20% de Colesterol; 10% de Diestearoilfosfatidilglicerol (DSPG), 1,3% de 2,6 - bis (1,1-dimetil) - 4 - metil fenol (BHT) e 7% de Nistatina, a caracterização fisico-química do sistema e a investigação da atividade biológica, pelo teste de susceptibilidade. As preparações foram testadas com leveduras dos gêneros Candida e Cryptococcus. A formulação lipossomal com o fármaco nistatina aplica-se, especialmente, aos indivíduos portadores de miscoses sistémicas, tais como: os imunodeprimidos.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0704816A BRPI0704816B8 (pt) | 2007-12-17 | 2007-12-17 | formulação lipossomal com o fármaco nistatina |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0704816A BRPI0704816B8 (pt) | 2007-12-17 | 2007-12-17 | formulação lipossomal com o fármaco nistatina |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0704816A2 true BRPI0704816A2 (pt) | 2009-08-11 |
| BRPI0704816B1 BRPI0704816B1 (pt) | 2020-09-24 |
| BRPI0704816B8 BRPI0704816B8 (pt) | 2022-07-19 |
Family
ID=40942033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0704816A BRPI0704816B8 (pt) | 2007-12-17 | 2007-12-17 | formulação lipossomal com o fármaco nistatina |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BRPI0704816B8 (pt) |
-
2007
- 2007-12-17 BR BRPI0704816A patent/BRPI0704816B8/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0704816B1 (pt) | 2020-09-24 |
| BRPI0704816B8 (pt) | 2022-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ye et al. | Polyhydroxylated fullerene attenuates oxidative stress-induced apoptosis via a fortifying Nrf2-regulated cellular antioxidant defence system | |
| Manosroi et al. | Stability and transdermal absorption of topical amphotericin B liposome formulations | |
| Shi et al. | Incorporation of β-sitosterol into the membrane increases resistance to oxidative stress and lipid peroxidation via estrogen receptor-mediated PI3K/GSK3β signaling | |
| Serpe et al. | Influence of salivary washout on drug delivery to the oral cavity using coated microneedles: an in vitro evaluation | |
| Janůšová et al. | Amino acid derivatives as transdermal permeation enhancers | |
| BR112015026601A2 (pt) | método para um ensaio de triagem de fármaco à base de células e o uso do mesmo | |
| Hendrich et al. | Differential interaction of Sophora isoflavonoids with lipid bilayers | |
| Vater et al. | Lecithin-based nanoemulsions of traditional herbal wound healing agents and their effect on human skin cells | |
| Zhang et al. | Evaluation of skin viability effect on ethosome and liposome-mediated psoralen delivery via cell uptake | |
| Jantas et al. | The attenuating effect of memantine on staurosporine-, salsolinol-and doxorubicin-induced apoptosis in human neuroblastoma SH-SY5Y cells | |
| BRPI1006790B8 (pt) | método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico | |
| Clitherow et al. | Medium-chain fatty acids released from polymeric electrospun patches inhibit Candida albicans growth and reduce the biofilm viability | |
| Sunasee et al. | Cellulose nanocrystal cationic derivative induces NLRP3 inflammasome-dependent IL-1β secretion associated with mitochondrial ROS production | |
| Pravdic et al. | Complex I and ATP synthase mediate membrane depolarization and matrix acidification by isoflurane in mitochondria | |
| TR201809514T4 (tr) | Uzun süre etkili insülin formülasyonları. | |
| BRPI0908942A2 (pt) | Sistemas de distribuição de fármacos compreendendo fármacos fracamente básicos e ácidos orgânicos | |
| BRPI0615292A8 (pt) | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada | |
| MX389730B (es) | Extinguidor que contiene nanomaterial conjugado con polimero soluble en agua y su uso. | |
| Prylutskyy et al. | Interaction of C60 fullerene complexed to doxorubicin with model bilipid membranes and its uptake by HeLa cells | |
| Alonso et al. | Interaction of miltefosine with intercellular membranes of stratum corneum and biomimetic lipid vesicles | |
| BR112013023970A2 (pt) | composição farmacêutica, dispositivo, inibidor de hdac, kit, método de pré-tratamento de um ser humano que sofre de câncer e método de avaliação do efeito de uma substância sobre a sensibilidade a chop de linhagens celulares | |
| BR112014026582A2 (pt) | método para identificar agentes capazes de induzir a sensibilização respiratória e matriz e kits analíticos para uso no método | |
| Ma et al. | Antagonistic effect of protein extracts from Streptococcus sanguinis on pathogenic bacteria and fungi of the oral cavity | |
| Hosmer et al. | Influence of internal structure and composition of liquid crystalline phases on topical delivery of paclitaxel | |
| AR092840A1 (es) | Elaboracion de degarelix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06V | Preliminary requirement: patent application procedure suspended [chapter 6.22 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2594 DE 24/09/2020 QUANTO AO INVENTOR. |
|
| B25C | Requirement related to requested transfer of rights |
Owner name: UNIVERSIDADE ESTADUAL DE MARINGA (BR/PR) Free format text: A FIM DE ATENDER A TRANSFERENCIA DE PARTE DOS DIREITOS, REQUERIDA ATRAVES DA PETICAO NO 870220097689 DE 24/09/2020, E NECESSARIO APRESENTAR DOCUMENTO QUE COMPROVE QUE O REPRESENTANTE DA CEDENTE TEM PODERES PARA REALIZAR TAL ATO. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
| B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: UNIVERSIDADE ESTADUAL DE MARINGA (BR/PR) Free format text: RETIFICACAO DO DESPACHO 25.3 ? TRANSFERENCIA EM EXIGENCIA PUBLICADO NA RPI NO 2719, DE 14/02/2023.ONDE SE LE: REQUERIDA ATRAVES DA PETICAO NO 870220097689 DE 24/09/2020.LEIA-SE: REQUERIDA ATRAVES DA PETICAO NO 870220097689 DE 21/10/2022. |
|
| B25C | Requirement related to requested transfer of rights |
Owner name: UNIVERSIDADE ESTADUAL DE MARINGA (BR/PR) Free format text: A FIM DE ATENDER A TRANSFERENCIA DE PARTE DOS DIREITOS, REQUERIDA ATRAVES DA PETICAO NO 870230026274 DE 29/03/2023, E NECESSARIO APRESENTAR DOCUMENTO QUE COMPROVE QUE A PESSOA QUE ASSINOU O DOCUMENTO DE CESSAO TINHA PODERES PARA REALIZAR TAL ATO, UMA VEZ QUE O NOME DO REITOR QUE ASSINOU O DOCUMENTO DE CESSAO NA PETICAO 870220097689 DE 21/10/2022 E DIFERENTE DONOME DO REITOR QUE CONSTA NO DOCUMENTO APRESENTADO NA PETICAO 870230026274 DE 29/03/2023. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
| B25A | Requested transfer of rights approved |
Owner name: UNIVERSIDADE ESTADUAL DE MARINGA (BR/PR) ; UNIVERSIDADE ESTADUAL DE CAMPINAS (BR/SP) |